EP2238457A1 - Nouveau procédé pour évaluer si des symptômes chez un patient sont liés à une hypersensibilité à un allergène spécifique - Google Patents

Nouveau procédé pour évaluer si des symptômes chez un patient sont liés à une hypersensibilité à un allergène spécifique

Info

Publication number
EP2238457A1
EP2238457A1 EP08853942A EP08853942A EP2238457A1 EP 2238457 A1 EP2238457 A1 EP 2238457A1 EP 08853942 A EP08853942 A EP 08853942A EP 08853942 A EP08853942 A EP 08853942A EP 2238457 A1 EP2238457 A1 EP 2238457A1
Authority
EP
European Patent Office
Prior art keywords
allergen
immunoglobulin
type
amount
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08853942A
Other languages
German (de)
English (en)
Other versions
EP2238457A4 (fr
Inventor
Lars Söderström
Staffan Ahlstedt
Per Matsson
Adnan Custovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phadia AB
Original Assignee
Phadia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phadia AB filed Critical Phadia AB
Publication of EP2238457A1 publication Critical patent/EP2238457A1/fr
Publication of EP2238457A4 publication Critical patent/EP2238457A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Definitions

  • the present invention relates to the field of allergic diseases, and especially to methods for assessing if symptoms in a patient are related to a hypersensitivity to a specific allergen.
  • the present invention relates to a method for obtaining a parameter for assessing if symptoms in a subject are related to a hypersensitivity to an allergen or allergen component, comprising the steps - obtaining from said patient a body fluid sample containing immunoglobulins; - determining the amount in the sample of a first type of immunoglobulin binding specifically to said allergen or allergen component;
  • said first and second types of immunoglobulins are selected from the group consisting of IgA, IgD, IgE, IgG and IgM, such as IgG or IgE or subtypes thereof, such as IgG4.
  • the step of relating the amount of said first type of immunoglobulin to the amount of said second type of immunoglobulin in said sample comprises the formation of a ratio between the amounts of said first and second immunoglobulin, respectively.
  • the amount of said first and/or second type of immunoglobulins, respectively is a sum of serum immunoglobulins.
  • the allergen is preferably a respiratory allergen and may come from a number of allergen sources such as animals and plants, e.g. cat, cockroach, dog, mouse, grass pollen, tree pollen, horse, house dust mites, moulds and/ or olive pollen.
  • animals and plants e.g. cat, cockroach, dog, mouse, grass pollen, tree pollen, horse, house dust mites, moulds and/ or olive pollen.
  • the symptoms may be any allergy like or allergy related symptoms , such as persistent wheeze, asthma, rhinitis, rhino-conjunctivitis, eczema etc.
  • the invention in a second aspect relates to a method for assessing if symptoms in a subject are related to a hypersensitivity to an allergen, comprising the steps
  • the invention relates to a method for assessing if symptoms in a subject are related to a hypersensitivity to an allergen, comprising the steps
  • the subject in the above mentioned aspects may be either a human or an animal.
  • the determination of amounts of immunoglobulins in the sample from the subject may be done by conventional methods used in the art, e.g. by ImmunoCAP (Phadia AB, Uppsala, Sweden), immunoassays such as ELISA, microarrays etc.
  • ImmunoCAP Phadia AB, Uppsala, Sweden
  • immunoassays such as ELISA, microarrays etc.
  • the invention in a fourth aspect relates to computer program products directly loadable into the internal memory of a processing means associated with an apparatus for analysis of binding assays, comprising the software code means adapted for controlling the steps of the method according to the first or second aspect.
  • the invention in a fifth aspect relates to an apparatus for analysis of binding assays, said apparatus being adapted to perform the method according to the first or second aspect and comprising
  • FIG. 5 A schematic drawing of such an apparatus is given in Figure 5.
  • the above described means should typically be regarded as software defined functional means in the digital processing parts of the apparatus, i.e. not necessarily physical entities.
  • the apparatus may be incorporated into one physical apparatus, such as a desk top computer, but may also be distributed over a number of physical apparatuses, such as servers, located at different locations.
  • Figure 1 Fitted predicted probability curve for persistent wheeze at a given cat-specific IgE value and FeI d 1 -specific IgG value derived from the multivariate logistic regression analysis. Higher IgE antibody level to cat is associated with higher probability of allergic disease, wheeze or asthma, in the presence of low IgG antibody level. Higher IgG antibody level decrease this association.
  • Figure 2 Fitted predicted probability curve for persistent wheeze at a given cat-specific IgE value and FeI d 1 -specific IgG4 value derived from the multivariate logistic regression analysis. Higher IgE antibody level to cat is associated with higher probability of allergic disease, wheeze or asthma. Higher IgG4 antibody level does not change this association.
  • Figure 3 Fitted predicted probability curve for the association between cumulative FeI d 1 exposure during the first five years of life, cat-specific IgE value and FeI d 1 -specific IgG value derived from the multivariate logistic regression analysis. Higher exposure to cat is associated with higher level of IgE and IgG antibody.
  • Figure 4 Fitted predicted probability curve for the association between cumulative FeI d 1 exposure during the first five years of life, cat-specific IgE value and FeI d 1 -specific IgG4 value derived from the multivariate logistic regression analysis. Higher exposure to cat is associated with higher level of IgE and IgG4 antibody.
  • Figure 5 Schematic drawing of an apparatus according to the fifth aspect of the invention.
  • Allergen source should in the context of the present invention be construed as the organism from which an allergen is derived, such as cat, dog, birch etc.
  • Allergen should in the context of the present invention be construed as a hyposensitizing environmental agent derived from an allergen source, such as an extract from grass pollen or dog dander etc.
  • Allergen component should in the context of the present invention be construed as an isolated or recombinantly produced molecule being a component of an allergen, such as FeI d 1 from cat, PhI p 1 from timothy grass etc.
  • the allergen is derived from cat
  • the immunoglobulins are IgG, IgG 4 and IgE
  • the symptoms related to hypersensitivity is wheeze.
  • METHODS Study Population The Manchester Asthma and Allergy Study is an unselected population-based birth cohort study described in detail elsewhere (12, 13). Subjects were recruited from the antenatal clinics when all pregnant women (first trimester of pregnancy) were screened for eligibility. Both parents completed a questionnaire and skin prick testing. Children were followed prospectively and attended review clinics at age three and five years ( ⁇ four weeks). The study was approved by the Local Research Ethics Committee. Written informed consent was obtained from subjects' families, and children gave their assent.
  • a validated questionnaire (14) was interviewer-administered to collect information on parentally reported symptoms, physician-diagnosed illnesses and treatments received. Children were defined as having current wheeze if they had wheezing in the previous 12 months at age five years. In addition, we assigned children into different wheeze phenotypes according to history of wheeze at the two follow-ups (15): No wheezing -no wheeze during the first three years of life, no wheezing ever by age five;
  • rFel d 1 Allergen ImmunoCAP were used.
  • rFel dl was produced by Phadia AB and subsequently coupled to the solid phase of flexible, hydrophilic, cellulose sponge polymer matrix activated by CNBr chemistry.
  • the purified components were covalently coupled to the activated solid phase via the amino groups of the proteins according to standard in house methodology as previously described (18).
  • the primary outcome measure was "Persistent wheeze" at age five years.
  • the relationship between antibody responses and outcome measure was analyzed using logistic regression. Odds ratios (OR) were estimated using the regression models and 95% confidence intervals (95% CI) were generated according to
  • WaId using a p-value of 0.05 as significant. Fitted predicted probability curves were plotted using the results from the logistic regression.
  • IgE IgG
  • IgG4 antibody production In the susceptible individual the IgE antibody level is mostly associated with clinical disease triggered by exposure to the allergen. However, it is also well known that extensive exposure can lead to IgG and IgG4 antibody formation but no expression of disease.
  • the present invention establishes quantitatively the negative impact of IgG, but not IgG4, antibody on the association between the presence of IgE antibody and clinical disease.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention porte sur le domaine des maladies allergiques et particulièrement sur des procédés pour évaluer si des symptômes chez un patient sont liés à une hypersensibilité à un allergène spécifique. L'invention porte en outre sur un produit de programme informatique incluant des moyens pour contrôler les étapes desdits procédés pour une utilisation avec un appareil d'analyse de dosages de liaison. L'invention porte également sur un tel appareil.
EP08853942A 2007-11-30 2008-12-01 Nouveau procédé pour évaluer si des symptômes chez un patient sont liés à une hypersensibilité à un allergène spécifique Withdrawn EP2238457A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99132307P 2007-11-30 2007-11-30
SE0702681 2007-11-30
PCT/SE2008/051385 WO2009070122A1 (fr) 2007-11-30 2008-12-01 Nouveau procédé pour évaluer si des symptômes chez un patient sont liés à une hypersensibilité à un allergène spécifique

Publications (2)

Publication Number Publication Date
EP2238457A1 true EP2238457A1 (fr) 2010-10-13
EP2238457A4 EP2238457A4 (fr) 2011-03-16

Family

ID=40678848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08853942A Withdrawn EP2238457A4 (fr) 2007-11-30 2008-12-01 Nouveau procédé pour évaluer si des symptômes chez un patient sont liés à une hypersensibilité à un allergène spécifique

Country Status (3)

Country Link
EP (1) EP2238457A4 (fr)
JP (1) JP2011505557A (fr)
WO (1) WO2009070122A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017195871A1 (fr) * 2016-05-13 2017-11-16 応用酵素医学研究所株式会社 Procédé permettant de collecter des données pour prédire le risque de développer des allergies
EP3685402B1 (fr) * 2017-09-23 2024-06-26 TPS Production Srl Procédé de corrélation de symptômes allergiques et d'allergènes
IT201700106602A1 (it) * 2017-09-23 2019-03-23 Tps Production Srl Approcci multivariati allo studio delle relazioni tra sintomi e allergeni

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JAMES ET AL: "Immunologic changes associated with the development of tolerance in children with cow milk allergy", JOURNAL OF PEDIATRICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, vol. 121, no. 3, 1 September 1992 (1992-09-01), pages 371-377, XP022366517, ISSN: 0022-3476, DOI: DOI:10.1016/S0022-3476(05)81788-3 *
JARVIS ET AL: "Cat and dust mite allergen levels, specific IgG and IgG4, and respiratory symptoms in adults", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 119, no. 3, 9 March 2007 (2007-03-09) , pages 697-704, XP022004975, ISSN: 0091-6749, DOI: DOI:10.1016/J.JACI.2006.10.042 *
JEEP S ET AL: "IGE IGG IGG1 AND IGG4 PATTERNS IN YELLOW JACKET ALLERGIC PATIENTS DURING IMMUNOTHERAPY WITH A VENOM DEPOT EXTRACT", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 22, no. 2, 1992, pages 297-302, XP002620105, ISSN: 0954-7894 *
JONES ET AL: "Is the Attenuation in Risk of Sensitisation and Wheezing observed at High Allergen Exposures due to a Modified Th Response?", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 119, no. 1, 1210, 1 January 2007 (2007-01-01), page S310, XP005757123, ISSN: 0091-6749, DOI: DOI:10.1016/J.JACI.2006.12.583 *
NAITO K ET AL: "Specific IgE and IgG4 antibodies to Japanese cedar pollen and total IgE antibody in lumbermen", AEROBIOLOGIA 1998 IE, vol. 14, no. 4, 1998, pages 321-324, XP002620104, ISSN: 0393-5965 *
NOH GEUNWOONG ET AL: "The clinical significance of food specific IgE/IgG4 in food specific atopic dermatitis.", PEDIATRIC ALLERGY AND IMMUNOLOGY : OFFICIAL PUBLICATION OF THE EUROPEAN SOCIETY OF PEDIATRIC ALLERGY AND IMMUNOLOGY FEB 2007 LNKD- PUBMED:17295801, vol. 18, no. 1, February 2007 (2007-02), pages 63-70, XP002620101, ISSN: 0905-6157 *
OKAZAKI M ET AL: "Specific IgE, IgG and IgG4 antibodies against house dust mite in patients with bronchial asthma", ACTA MEDICA OKAYAMA, OKAYAMA, JP, vol. 45, no. 4, 1 August 1991 (1991-08-01) , pages 267-273, XP008132527, ISSN: 0386-300X *
ONER AHMENT FAIK ET AL: "Serum immunoglobulins and immunoglobulin G subclasses with recurrent wheezing", INDIAN JOURNAL OF PEDIATRICS, vol. 67, no. 12, December 2000 (2000-12), pages 861-864, XP002620102, ISSN: 0019-5456 *
See also references of WO2009070122A1 *
SIMPSON ET AL: "IgE antibody quantification and the probability of wheeze in preschool children", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 116, no. 4, 1 October 2005 (2005-10-01), pages 744-749, XP005094462, ISSN: 0091-6749, DOI: DOI:10.1016/J.JACI.2005.06.032 *
SLETTEN GAYNOUR B G ET AL: "Changes in humoral responses to beta-lactoglobulin in tolerant patients suggest a particular role for IgG4 in delayed, non-IgE-mediated cow's milk allergy.", PEDIATRIC ALLERGY AND IMMUNOLOGY : OFFICIAL PUBLICATION OF THE EUROPEAN SOCIETY OF PEDIATRIC ALLERGY AND IMMUNOLOGY SEP 2006 LNKD- PUBMED:16925689, vol. 17, no. 6, September 2006 (2006-09), pages 435-443, XP002620103, ISSN: 0905-6157 *
SRIVASTAVA D ET AL: "Immunotherapy with mosquito (Culex quinquefasciatus) extract: a double-blind, placebo-controlled study", ANNALS OF ALLERGY, ASTHMA & IMMUNOLOGY, ARLINGTON HEIGHTS, IL, US, vol. 99, no. 3, 1 September 2007 (2007-09-01), pages 273-280, XP026959878, ISSN: 1081-1206 [retrieved on 2007-09-01] *

Also Published As

Publication number Publication date
EP2238457A4 (fr) 2011-03-16
WO2009070122A1 (fr) 2009-06-04
JP2011505557A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
Siroux et al. Specific IgE and IgG measured by the MeDALL allergen-chip depend on allergen and route of exposure: the EGEA study
Lupinek et al. Maternal allergen-specific IgG might protect the child against allergic sensitization
Westman et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence
Linneberg et al. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study
Vereda et al. Peanut allergy: clinical and immunologic differences among patients from 3 different geographic regions
Kuehr et al. Mite allergen exposure is a risk for the incidence of specific sensitization
Donohue et al. Anti-cockroach and anti-mouse IgE are associated with early wheeze and atopy in an inner-city birth cohort
Gold et al. Predictors of repeated wheeze in the first year of life: the relative roles of cockroach, birth weight, acute lower respiratory illness, and maternal smoking
Platts-Mills et al. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study
Gent et al. Association of pediatric asthma severity with exposure to common household dust allergens
Bolte et al. Early endotoxin exposure and atopy development in infants: results of a birth cohort study
Portengen et al. Endotoxin exposure and atopic sensitization in adult pig farmers
Ahlstedt Understanding the usefulness of specific IgE blood tests in allergy.
Chen et al. Longitudinal study on cat allergen exposure and the development of allergy in young children
Ott et al. Total serum IgE as a parameter to differentiate between intrinsic and extrinsic atopic dermatitis in children
Epstein et al. Opposing effects of cat and dog ownership and allergic sensitization on eczema in an atopic birth cohort
Joseph et al. Blood lead level and risk of asthma
Jøhnke et al. Patterns of sensitization in infants and its relation to atopic dermatitis
Grönlund et al. Higher immunoglobulin E antibody levels to recombinant Fel d 1 in cat‐allergic children with asthma compared with rhinoconjunctivitis
Williams et al. Gene-environment interactions with CD14 C-260T and their relationship to total serum IgE levels in adults
Soomro et al. Prenatal exposure to phthalates and the development of eczema phenotypes in male children: results from the EDEN Mother–Child Cohort Study
Westman et al. Sensitization to grass pollen allergen molecules in a birth cohort—natural Phl p 4 as an early indicator of grass pollen allergy
Chew et al. Cockroach allergen levels and associations with cockroach-specific IgE
Yamamoto-Hanada et al. IgE responses to multiple allergen components among school-aged children in a general population birth cohort in Tokyo
Kumar et al. Factors associated with degree of atopy in Latino children in a nationwide pediatric sample: the Genes-environments and Admixture in Latino Asthmatics (GALA II) study

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110914